Table 1.
Characteristics of 49 patients with ovarian mucinous carcinoma according to invasive patterns
| Ovarian mucinous carcinoma with infiltrative invasion |
Ovarian mucinous carcinoma with expansile invasion |
p-Value | |
|---|---|---|---|
| Variables | n = 25 | n = 24 | |
| Age (years) | 0.16 | ||
| < 51 | 16 (64) | 10 (42) | |
| ≥ 51 | 9 (36) | 14 (58) | |
| FIGO stage (%) | 0.26 | ||
| I | 16 (64) | 20 (84) | |
| II | 1 (4) | 1 (4) | |
| III | 6 (24) | 1 (4) | |
| IV | 2 (8) | 2 (8) | |
| Tumor site (%) | 0.35 | ||
| Unilateral | 21 (84) | 23 (96) | |
| Bilateral | 4 (4) | 1 (4) | |
| Standard surgery (%) | 0.78 | ||
| Yes | 15 (60) | 13 (54) | |
| No | 10 (40) | 11 (46) | |
| Peritoneal cytology (%) | 0.78 | ||
| Positive | 12 (48) | 10 (42) | |
| Negative | 13 (52) | 14 (58) | |
| Residual tumor diameter at PDS (%) | 0.58 | ||
| No residual tumor | 18 (72) | 20 (83) | |
| < 1.0 cm | 1 (4) | 1 (4) | |
| ≥ 1.0 cm | 6 (24) | 3 (13) | |
| Adjuvant chemotherapy (%) | 0.02 | ||
| Not done | 4 (16) | 12 (50) | |
| Done | 21 (84) | 12 (50) | |
| Regimen of the adjuvant chemotherapy | |||
| Paclitaxel and carboplatin | 5 (24) | 2 (17) | 0.20 |
| Platinum-based therapy a | 16 (76) | 10 (83) | |
| Response rate of adjuvant chemotherapy for patients with residual tumor which received adjuvant chemotherapy (%) | 0.20 | ||
| CR/PR | 3 (43) | 3 (100) | |
| S D/PD | 4 (57) | 0 (0) | |
| Recurrence (%) | < 0.01 | ||
| Yes | 13 (52) | 2 (8) | |
| No | 12 (48) | 22 (92) |
Abbreviations:SD standard deviation; FIGO International Federation of Gynecology and Obstetrics; PDS primary debulking surgery; cm centimeter; CR complete response; PR partial response; SD stable disease; PD progressive disease
a Platinum-based therapy included the combination with cyclophosphamide, doxorubicin, and cisplatin, the combination with cyclophosphamide and cisplatin, the combination with etoposide and cisplatin, and the combination with irinotecan and nedaplatin